initi coverag neutral tp
target difficult-to-treat diseas balanc larg commerci
opportun lead high option month
develop solubl guanyl cyclas sgc stimul could
multipl benefici effect first sgc modul approv
treatment pulmonari hypertens bayer adempa compani
enhanc
pharmacokinet profil specif tissue-target compani lead
asset olinciguat studi treat sickl cell diseas scd
data support approach differ diseas mix
note support olinciguat preclin data retrospect case seri data
adempa review biolog
compound differenti owe
scd market offer substanti risk/reward opportun think
scd market could larg time combin therapi
like adopt suggest substanti potenti opportun
result provid strong risk/benefit signal addit
cycn scd program compani also pursu cns-relat disord
high unmet need potenti provid lt option investor
offer multipl opportun lack clinic evid
limit convict believ key event share proof-of-
concept data olinciguat scd program though note
share could influenc interim possibl updat
on-going investigator-l relat drug adempa scd
praliciguat target partnership data heart failur
preserv eject fraction diabet nephropathi expect
lesser share impact olinciguat program view
initi neutral target price tp base dcf project
model discount rate probabl
success olinciguat risk includ clinic financ regulatori
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
cyclerion develop solubl guanyl cyclas sgc stimul
activ no-cgmp pathway address broad rang
seriou orphan diseas
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario reflect posit readout
olinciguat praliciguat lead increas po
hfpef dn respect
well increas weight
grey sky scenario reflect failur olinciguat
praliciguat lead termin program would
expect stock trade close net cash
 close
initi cyclerion neutral rate target price
cyclerion focus develop small molecul solubl guanyl cyclas sgc
stimul design mimic effect nitric oxid ubiquit
signal molecul numer effect vasodil anti-inflamm
believ investor assign major compani valu olinciguat
treatment sickl cell diseas scd scd seriou disord high unmet need
believ precipic evolv multi-billion-dollar market opportun
patient like manag combin complimentari therapi
olinciguat valu diseas difficult determin pend clinic data
competit profil could support drug potenti littl
mix clinic data avail scd use similar approach convict
olinciguat efficaci limit point olinciguat preclin data overlap
patholog diseas potenti role potenti mediat
support cycn develop strategi olinciguat
compani second clinically-advanc asset praliciguat treatment
diabet nephropathi dn heart failur preserv eject fraction hfpef
program earmark out-licens data support busi develop
activ readout expect cyclerion also develop sever sgc
program target differ organ liver lung
though preclin data olinciguat praliciguat support case
potenti benefit sgc stimul
heterogen multifactori driven
pathogenesi diseas suggest cautiou approach prudent data need
posit clinic meaning rel competit option drive valu higher
recent decis push develop timelin olinciguat scd
may also rais question driven on-going pk studi
olinciguat unblind safeti data on-going support addit
higher dose cohort studi model olinciguat achiev sale
po hfpef po dn po
praliciguat royalti tp base dcf project
model discount rate risk includ clinic financ regulatori
credit suiss biotech short-term outlook expect cyclerion range-
bound ahead pend clinic readout think market unlik gain
convict support higher program po olinciguat praliciguat without addit
support data note presenc on-going investigator-sponsor studi
relat drug adempa scd may updat ahead olinciguat
readout could meaning readthrough praliciguat note relat
drug merck vericiguat may data readout hfpef ye
credit suiss biotech long-term outlook view investor keenli
focus data olinciguat scd data readout expect note
global blood current carri
market cap basi establish proof-of-concept lead asset scd
credit suiss biotech outlook believ interest may begin build
stock price cyclerion demonstr olinciguat viabl treatment option
scd patient given larg rel under-penetrated market us eu
patient pharmaceut larg biopharmaceut compani presenc
hematolog could emerg potenti acquir
sgc stimul effect scd
preclin data shown olinciguat abil downregul
biomark directli associ inflamm scd
upregul gamma-globin gene directli associ
product fetal hemoglobin hbf address two major
compon drive complic associ scd
olinciguat could pose effect treatment option
scd complex diseas complic
predomin driven red blood cell sickl
compound directli revers stymi process
fail show meaning benefit long term defici
mere compon multifactori diseas therefor
provid margin benefit correct
posit preclin data notwithstand cautiou regard data translat human compani
announc top-lin data owe inclus cohort higher dose current studi could signal
efficaci may issu concern necessari dose produc clinic meaning result could eventu
compromis safeti profil hypotens one largest safeti concern increas cgmp activ
dearth treatment option brand product
launch scd patient us
eu standard care soc hydroxyurea low
adher rate void give substanti opportun novel
agent show meaning benefit toler safeti
profil given complex diseas combin therapi
expect multipl winner would reason scenario
olinciguat mover market share limit
without superior data multipl orphan-pr drug
sustain larg patient popul owe payor
believ scd market potenti evolv one similar pulmonari hypertens market
orphan diseas high unmet need ph treat multipl compound differ mechan action though
olinciguat could market drug first-in-class agent could gain traction variou combin set
addit olinciguat may abl carv nich physician may favor sgc stimul scd patient
accompani ph group given anoth sgc stimul bayer adempa fda approv treatment
patient ph group
sgc stimul diseas
fda approv adempa ph
encourag data bayer/merck sgc stimul vericiguat
shown patient heart failur preserv eject
fraction confer optim potenti moa
clinic trial graveyard compound
design increas system diseas report
scarciti compound diseas larg driven
defici well-defin
take account preval defici multitud diseas cgmp regulatori effect system
homeostasi lead us believ no-independ sgc stimul potenti differenti approach howev sgc
stimul shown benefit diseas grow bodi evid sgc stimul ineffect sever
differ diseas state believ optim abil identifi sub popul defici other within
diseas state and/or develop organ-specif sgc stimul diseas primarili afflict singl organ could viabl option
elucid potenti drug class
praliciguat top-line result dn
praliciguat top-line result hfpef
olinciguat top-line result scd
olinciguat well-character moa high
option signific sickl cell market
sickl cell diseas multifactori monogen disord afflict individu
adult children global character chronic pain veno-occlus
crise lead multipl hospit annual current soc provid
benefit limit low adher rate potenti toxic
preclin data suggest olinciguat moa may offer benefici intervent clinic
data support limit time clinic data relat approach
limit inconclus far data olinciguat expect
determin proof concept
scd current limit option treatment high unmet need persist
burgeon pipelin differ moa ahead compet
olinciguat believ treatment scd like evolv combin
therapi time support multipl target therapi envis market
opportun olinciguat clinic profil determin market penetr potenti
sickle-cel diseas sever affect mani across globe
scd patient suffer acut chronic pain result hospit
lead caus mortal scd pulmonari hypertens heart diseas renal
complic end-stag renal diseas mortal rate high popul
life expect reduc year
scd monogen disord caus point mutat beta-globin gene form
hb caus product sickl red blood cell way deoxygenation-
induc polymer hb lead manifest differ genotyp sever
variant highli express
hbss homozyg inherit often refer sickl cell anemia
common character sever form scd
hbsc heterozyg inherit milder form scd
hbs/beta thalassemia coinherit bs b-thalassemia gene
low non-exist mrna product normal b-globin often
sever hbss bthal patient spectrum clinic sever
scd common genet hematolog disord world affect
us center diseas control prevent given diseas predominantli
affect individu african descent other higher preval
region sub-saharan africa mediterranean basin middl east india
charl martineau univers toronto scd activ multipl pathway lead poor outcom
figur scd multifactori diseas
chronic potenti life-threaten diseas character multipl
potenti druggabl patholog driven sickl rbc
activ endotheli cell sickl rbc express adhes molecul
result increas virtual major adhes pathway includ integrin
receptor immunoglobin famili member endotheli
selectin solubl adhes protein thrombospondin fibrogen fibronectin
von factor mani expos membran compon
destruct releas plasma-fre hemoglobin scaveng lead
endotheli dysfunct also releas heme iron major caus oxid
e-selectin express
recruit adher
white blood cell adhes in-vitro studi reveal sickl rbc
directli bind activ neutrophil attach shown decreas
blood vessel diamet increas blood flow resist
sickl rbc also lead hallmark complic scd vaso-occlus crise
voc though voc link sickl element heterogen
drive present voc may trigger inflamm stress increas
blood viscos decreas flow hemolysi complic scd primari
caus hospit
current therapeut option limit
hydroxyurea chemotherapeut agent origin approv treat
resist chronic myeloid leukemia local advanc squamou cell carcinoma
head neck approv treat scd heavili generic
believ work multipl mechan increas fetal hemoglobin hbf reduc
rbc procliv sickl nitric oxid gener vasodilatori properti
reduct adhes sickl cell cell endothelium decreas
express level solubl anti-inflammatori precis known much
clinic benefit hydroxyurea attribut increas hbf level compar
activ major may ascrib given biolog diseas
hydroxyurea well-known dose-limit toxic myelosuppress carri
black box warn well increas risk malign also
concern relat fertil howev multipl studi demonstr hydroxyurea
gener well toler safe scd patient includ children physician
spoke corrobor outcom studi encount mani
ae-rel issu gener view risk benefit reason favor
poor adher gener associ hydroxyurea physician well
literatur estim scd patient routin take hydroxyurea portion
patient high patient accord kol opt take drug due
safeti concern side evid suggest physician
prescrib drug often titrat difficulti need
laboratori monitor treatment lastli children adult
respond treatment reason fulli understood manwani deepa
endari emmanu life scienc fda approv juli endari pharmaceut
grade version l-glutamin essenti amino acid drug util
monotherapi combin hydroxyurea physician spoken
unimpress efficaci experienc thu far also
encount access issu payor given l-glutamin avail
counter insur less inclin provid coverag endari emmanu
disclos sale endari launch januari
bone marrow transplant bmt bmt recogn cure avail
scd patient howev lack avail match sibl donor significantli
limit treatment option less patient suitabl candid
olinciguat moa could address multipl pathway scd patholog
olinciguat solubl guanyl cyclas sgc stimul increas
signal lead activ differ pathway sgc intracellular
protein tissu throughout bodi bound bind
sgc lead product cyclic guanosin monophosph cgmp secondari
signal molecul promot vasodil within blood vessel reduc
platelet aggreg reduc leukocyt adhes
figur mechan action
preclin data olinciguat shown broad effect activ
no/cgmp pathway could lessen neg effect scd olinciguat slow
progress hemolyt anemia scd mous model figur normal
mrna express gamma-globin subunit hbf greater vehicl
cell figur attenu leukocyt endotheli cell activ
mous model inflamm figur
figur hemolyt anemia improv could confer reduct hemolysi
olinciguat potenti reduc sickl increas hbf
figur gamma globin express link hbf
figur reduct inflammatori marker support potenti reduc voc
strong-scd cyclerion on-going evalu safeti explor
preliminari efficaci sgc modifi approach diseas compani
determin whether pursu registr trial base data readout on-going
trial random pbo-control studi evalu olinciguat
safeti profil well efficaci endpoint includ pain crisi event biomark
diseas activ hbf level anemia inflammatori marker health-rel
patient-report outcom chronic pain fatigu studi power
show statist signific efficaci data gener could encourag
recent dose rang studi shown higher-than-expect dose may safe
use well toler result cyclerion recent amend strong-scd
trial includ four olinciguat dose cohort placebo group three olinciguat
cohort revis expect top-lin readout ad
olinciguat cohort higher dose studi intellectu properti
ip reason compani disclos exact dose cohort studi
subject includ hbss hbsc hbsbeta
experienc pain crise past year
moa preclin data olinciguat suggest potenti scd
concept rel unestablish clinic smaller
studi drug relat activ no/cgmp promot agent studi
gener investigator-initi and/or small conclus
sildenafil studi ph patient scd show potenti neg effect
nih-sponsor studi halt earli interim analysi patient
suggest elev safeti risk among trial patient week treatment
patient sildenafil arm significantli like experienc
voc episod requir hospit pbo patient vs
certainli encourag data point note sildenafil
capabl promot cgmp product presenc endogen
substrat oppos sgc stimul olinciguat directli
increas cgmp product irrespect endogen statu scd
associ reduc level difficult determin pro-cgmp effect
sildenafil condit
sgc stimul adempa riociguat evidenc encourag data scd
patient chronic thromboembol pulmonari hypertens cteph
weir nargu et al retrospect report case seri adempa
safe well toler patient discontinu due
intract headach month therapi persist gi effect month
therapi show decreas voc frequenc patient
year administr note patient reduct voc frequenc
also manag hydroxyurea patient see benefit
receiv transfus therapi suggest possibl ad benefit
sgc stimul util concomitantli hydroxyurea
could provid import clue help inform po olinciguat accord
clinicaltri gov page top line studi could avail
could allow public data present medic confer
later yearahead expect olinciguat data
addit sgc modul studi
indic gener mix data lead multipl program termin
said olinciguat clean track record thu far given indic
studi achalasia met primari endpoint program discontinu base
realloc capit toward promis market opportun scd
figur sgc modul presently/previ clinic develop
decid focu resourc
trial complet
studi pursu
primari endpoint met
accord ironwood
ocular hypertens
termin earli due
evid posit trend
posit trend poc studi
compani termin
trial complet publish
trial longer activ
longer list nv
pipelin publish result
charl martineau univers toronto olinciguat possibl within grow field scd option
competit landscap rife novel modal larg attribut
complex scd pathophysiolog past failur target therapi
primari endpoint incid treatment emerg advers event
biweekli
monthli
affin
oxygen
procedur
on-going sentri includ seven activ plan studi
number patient experienc voc year
addit data mg/kg arm
decreas annual rate voc vs
median time first on-treat voc vs month
increas time first voc treatment arm vs pbo vs month
arthralgia diarrhea pruritu vomit chest pain
part age
improv hgb g/dl baselin week hd vs ld vs pbo
mean chang hgb baselin week hd vs ld vs pbo
mean chang hgb hydroxyurea week hd vs ld vs pbo
number voc patient voc hd vs ld vs pbo
dose advers event lead discontinu
versu would use see detail dose
higher rate diarrhea versu arthralgia versu
patient month post treatment show nearli red blood cell lower
amount s/ s/a control sampl longer receiv
blood transfus time readout
patient month post treatment product gene therapy-deriv
hemoglobin rang g/dl compar exceed
level sickl hemoglobin hb patient receiv blood transfus
time total hemoglobin rang g/dl last visit
voc event report data cut-off nine month post treatment
exploratori analysi key marker hemolysi includ reticulocyt count lactat
dehydrogenas ldh total bilirubin concentr decreas compar baselin
go/no-go decis advanc
olinciguat clinic trial
novarti file approv
stand pt older
enrol patient dose
mg/kg studi start may
preliminari data may
submiss nda
also evalu safeti
pharmacokinet singl
multipl dose voxelotor
adolesc pediatr patient
scd phase clinic
addit data expect
ye
initi studi
voxelotor global blood voxelotor abil increas oxygen
affin hgb shown reduc sickl without induc hypoxemia
tissu increas hgb level part trial evidenc increas
hgb level averag g/dl show improv
hemolysi measur strike differ treatment
placebo arm number voc event rel differ compani
contend intent select healthier studi popul previous
mani voc focu show voxelotor well-toler
produc impact hgb level clinic benefit reduc hemolyt
anemia decid forego part go evalu
patient-report outcom much variabl data
despit mix reaction physician data post fda pre-nda
meet file acceler approv base part data
crizanlizumab novarti anti-p-selectin directli address inflamm
patholog scd block cell-adhes drug shown benefit reduct
annual rate sickl cell-rel pain crise unclear synonym
voc physician spoke suggest iv infus everi week first
month everi week thereaft may hinder broad adopt novarti plan
file approv
gene edit zynteglo crispr
expert spoke enthusiast potenti gene edit though
crispr current data agent physician particularli
keen bluebird zynteglo potenti consid data impress
believ expect high cost cumbersom procedur stem cell
harvest ex-vivo transduct myeloabl would posit approach
sever patient despit cur approach gene edit expect
substanti impact agent purpos manag scd
develop compani
pfizer/glycomimet modu therapeut prolong pharmaceut
studi agent treat scd focus util treat voc
view potenti complimentari olinciguat
see global opportun olinciguat evolv
clinic profil determin market penetr
given unmet need market nascenc multipl pathway contribut
scd complic believ room novel drug address variou
compon diseas similar evolut anoth vascular-driven rare
diseas pulmonari hypertens market expect combin therapi
drug non-overlap moa
eventu becom mainstay patient
manag singl modal outsid gene therapi like cur
manag also mention agenc support patient report outcom
endpoint base basket symptom pain fatigu olinciguat
current fda orphan design give year exclus
gener attempt enter market manag guid toward ip
protect
launch base olinciguat current stage develop
histor develop timelin agent plan file
approv near term
market share base third market mover competit
clinic profil make drug amen combin approach expect
penetr assumpt could chang possibl significantli clinic
profil olinciguat evolv
wac price model price would allow multipl
brand product incorpor scd treatment regimen see
rang defens base analysi compar
global sale could grow continu growth
base size unmet need market
hbss
year ent share yr peak
hbss
year ent share yr peak
price rel us
potenti option praliciguat area high
cyclerion develop anoth sgc stimul treat diseas burden larger
popul scd compani busi strategi focu address orphan
diseas state explor out-licens opportun event promis
data gener praliciguat
heart failur preserv eject fraction hfpef
million peopl us heart failur hfpef gazewood
john et al key differ hfpef heart failur reduc
eject fraction hfref hfpef pathophysiolog predominantli impact diastol
function heart lead abnorm pattern left ventricular fill elev
file pressur oppos weaken left ventricular suppli enough
blood meet bodi requir
heterogen hfpef make difficult treat despit difficulti physician
manag hfpef hfref similarli though much poorer outcom hfpef
fda-approv medic treat diseas clinic trial shown hf
mainstay beta blocker angiotensin convert enzym ace inhibitor
angiotensin receptor blocker arb decreas morbid mortal hfpef
rational potenti praliciguat hfpef
activ sgc cgmp impair hfpef patient deficit
hypothes involv cardiac dysfunct green stephen
merck/bay exploratori assess sgc stimul vericiguat
socrates-preserv trial yield mix result studi miss primari
endpoint reduct nt-probnp
demonstr
improv two well-establish patient report outcom composit kccq -pl
hfpef patient figur cleland et al merck explor
drug anoth trial vitality-hfpef evalu drug potenti top-line
figur vericiguat show posit result hfpef outcom
mg
mg mg
praliciguat preclin data show lower increas cardiac hypertrophi
inflamm measur level compar control high-salt mice though
standard anim model hfpef establish curl clair data
praliciguat demonstr suggest may activ human patient competitor
previous evidenc
charl martineau univers toronto figur praliciguat show improv hfpef-rel marker
praliciguat hfpef theoret multi-billion opportun
believ number candid clinic treat hfpef light full list appendix
primarili complex diseas praliciguat gener posit result
eventu commerci would one avail option avail
larg enough address market support multipl agent praliciguat could reason
achiev opportun peak clinic data support approv uptak novarti
entresto serv realist compar manag believ improv peak
could posit praliciguat attract target potenti licens partner
launch base praliciguat current stage develop
histor develop timelin agent advanc file
approv
market share us eu base competit market
dynam support trajectori compar current run rate
project novarti entresto hfref
wac price model price compar entresto
global sale could grow continu growth
base size unmet need market
royalti rate assum cyclerion abl broker mid-teen royalti
rate futur licens partner
preval hfpef patient
year ent share yr peak
preval hfpef patient
year ent share yr peak
price rel us
though precis mechan drive develop diabet nephropathi
known patient diabet develop overt dn nakagawa takahiko et
al dn tradit character presenc proteinuria albuminuria
presenc protein urin diabet patient addit comorbid
poor glycem control hypertens deterior glomerular hyperfiltr
higher risk develop dn
current treatment approach focus keep patient diabet control
inhibitor arb demonstr
fda-approv product class treat diseas capoten captopril cozaar
losartan avapro irbesartan renal-protect effect notwithstand ace inhibitor
arb mere slow loss renal function oppos directli revers
blood pressur ace
previou
trial non-dn
rational potenti praliciguat dn
endotheli dysfunct purport one major mechan potenti
dn johannes-pet stasch et al though literatur suggest diabet patient
produc mechan increas suppress earli stage dn
defici effici character patient sever prabhakar ss
stasch dellamea bruno et al inadequ activ link
poor control renal glomerular hemodynam
current ideal rodent model exhibit variou featur
human diabet nephropathi suffici amount diabet model mimic
renal dysfunct util explor possibl treatment kitada munehiro et
al praliciguat posit effect critic measur kidney function
high-salt mice suggest potenti viabl candid worth explor
charl martineau univers toronto figur marker reduc kidney function improv preclin data
figur top line data expect
cyclerion also conduct exploratori hypertens patient
praliciguat ad top patient soc statin use initi data suggest
direct sgc stimul provid ad benefit patient popul view
data could help better praliciguat posit hfpef dn
figur addit benefit praliciguat provid patient
dn larg commerci opportun competit increas
clinic develop pipelin grow inhibitor lead charg
comprehens list competit landscap locat appendix given posit
improv demonstr class trial primari indic
treatment type diabet challeng newcom gain appreci
urin albumin-to-creatinin ratio uacr reduct associ
reduc progress ckd mortal believ target rang investor
look futur present data
launch base praliciguat current stage develop histor
develop timelin agent advanc file approv
dn address popul literatur support third diabet
preval popul overt dn
treat patient cdc statist suggest less quarter dn
patient moderate-sever disposit awar diseas
use proxi patient diagnos treat
market share us eu base competit market dynam
wac price price point expect would
hfpef model price point still compar inhibitor price
global sale could grow continu growth
base size unmet need market
royalti rate assum cyclerion abl broker mid-teen royalti
rate futur licens partner
patient awar overt nephropathi proxi treat patient
year ent share yr peak
patient awar overt nephropathi proxi treat patient
year ent share yr peak
price rel us
addit upsid potenti cns-relat diseas directli target
liver lung
cyclerion studi potenti treat neurodegen
disord no/cgmp signal impair take advantag drug pk
profil allow cross blood brain barrier accumul
first patient on-going studi healthi volunt dose earli
compani plan present top line data
discoveri program cyclerion develop sgc stimul directli target
liver lung oral formul expect concentr liver address
inflammatori fibrot diseas inhal formul expect
concentr lung address pulmonari diseas caus exacerb
arriv target price use blend valuat approach includ
product-bas dcf valuat dcf valuat
dcf model assum discount rate account earli develop stage
compani fulli dilut share million long-term oper margin
tax rate assign pipelin account organ-
target compound discoveri detail dcf compon includ follow
 a-bas valuat scenario support reflect reduct
sg increas revenu account greater global opportun
assign weight dcf think scd
hematolog compani anoth scd-focus
compani later stage clinic develop global blood
therapeut gener interest
probabl success
standard probabl success assumpt phase asset
phase asset phase asset asset nda/bla stage
base histor drug develop data adjust made base histor
probabl success specif diseas categori standard mind
assign follow probabl success cyclerion pipelin
olinciguat base standard po assumpt olinciguat moa
biolog rational scd previous shown encourag preclin data
praliciguat lower standard po hfpef due
complex diseas mix data vericiguat show also
lower standard po dn due complex diseas
equival
compani cash cash equival march
project net cash use oper manag state enough
fund continu oper
blue sky scenario reflect posit readout olinciguat praliciguat
lead increas po hfpef
dn respect well increas weight grey sky
scenario reflect failur olinciguat praliciguat lead termin
program would expect stock trade close net cash
regulatory/clin risk trial enrol delay poorli design studi
inadequ endpoint enough power neg safety/efficaci signal
olinciguat failur scd and/or failur praliciguat dn hfpef
data attract enough out-licens praliciguat
manufacturing/suppli risk suppli disrupt product batch adher qualiti
standard manufactur shutdown due contamin technic difficulti
produc function complex molecul delay construction/certif new
lack materi compar among
inadequ
inabl manufactur suffici quantiti olinciguat meet clinic
commerci risk lower-than-expect adopt drug target popul
competit clinical/exist agent payor-impos access restrict price
access reimburs challeng olinciguat
competit multipl agent
research develop expens
sell gener administr expens
profit loss tax
weight average share use calcul dilut ep
cash equival
prepaid expens current asset
properti equip net
loss/ dispos fix asset
chang asset liabil
prepaid expens asset
net cash use oper activ
purchas properti equip
sale ppe
purchas invest
sale/matur invest
net cash use invest activ
transfer parent compani
proce issuanc debt
proce exercis stock option
payment note payabl stockhold
proce issuanc prefer stock net issuanc cost
proce issuanc common stock net
net cash use financ activ
net decreas increas cash cash equival
restrict cash begin period
restrict cash end period
primari endpoint incid treatment emerg advers event
rbc
primari endpoint incid treatment emerg advers event
reduct frequenc sickl cell crise hospit
compar placebo fewer crisi episod median vs median fewer
hospit sickl cell pain median vs median fewer day
hospit median day vs median day fewer occurr ac
addit find show decreas cumul hospit day percent
lower incid ac percent
pt constip nausea headach abdomin pain cough
back pain chest pain non-cardiac
biweekli
monthli
affin
oxygen
on-going sentri includ seven activ plane studi
number patient experienc voc year
addit data mg/kg arm
decreas annual rate voc vs
median time first on-treat voc vs month
increas time first voc treatment arm vs pbo vs
arthralgia diarrhea pruritu vomit chest pain
part age
improv hgb g/dl baselin week hd vs ld vs pbo
mean chang hgb baselin week hd vs ld vs pbo
mean chang hgb hydroxyurea week hd vs ld vs pbo
number voc patient voc hd vs ld vs pbo
dose advers event lead
discontinu versu would use see
detail dose higher rate diarrhea
versu arthralgia versu
go/no-go decis advanc
olinciguat clinic trial
approv age older
novarti file approv
stand pt older
enrol patient dose
preliminari data may
submiss nda
acceler approv
also evalu safeti
pharmacokinet singl
multipl dose voxelotor
adolesc pediatr patient
scd phase clinic trial
-month month doubl blind pbo-control random control trial
primari endpoint number voc
start
estim file us eu
primari endpoint incid treatment emerg advers event
procedur
procedur
level fetal
hemoglobin
patient month post treatment show nearli red blood cell
lower amount s/ s/a control sampl
longer receiv blood transfus time readout
patient month post treatment product gene therapy-
deriv hemoglobin rang g/dl
compar exceed level sickl hemoglobin hb patient
receiv blood transfus time total hemoglobin
rang g/dl last visit
voc event report data cut-off nine month post
treatment
exploratori analysi key marker hemolysi includ reticulocyt count
lactat dehydrogenas ldh total bilirubin concentr decreas
compar baselin
reduct sickl
blood vessel occlus
increas hbf preliminari data
addit data expect mid-
ye
initi studi
year open-label studi
select primari endpoint proport sustain hbf all-caus mortal
first patient enrol
expect infus
random multicent double-blind placebo-control studi evalu safeti
efficaci differ dose week patient hfpef
primari endpoint chang baselin peak cpet week incid
treatment-emerg advers event teae studi drug-rel teae
random double-blind active-control studi evalu effect entresto
compar valsartan cognit function patient chronic hfpef
primari endpoint chang baselin cogstat global cognit composit
score gcc week
random double-blind active-control studi evalu efficaci safeti
entresto compar valsartan morbid mortal heart failur patient nyha
class ii-iv hfpef
primari endpoint cumul number primari composit event cardiovascular cv
death total first recurr hf hospit month
random event-driven double-blind pbo-control studi hfpef patient
evalu effect dapagliflozin mg versu placebo given daili addit
background region standard care therapi includ treatment control co-
morbid reduc composit cv death heart failur event
primari endpoint time first occurr compon
composit cv death hospit hf urgent hf visit emerg
depart outpati visit month
random double-blind placebo-control studi evalu effect dapagliflozin
exercis capac patient hfpef
primari endpoint chang baselin walk distanc
random double-blind trial evalu efficaci safeti daili empagliflozin
mg compar placebo patient chronic hfpef
primari endpoint time first event adjud cv cardiovascular death
adjud hhf hospit heart failur patient hfpef
random double-blind trial evalu effect week treatment daili
mg compar placebo exercis abil heart failur symptom
patient chronic hfpef
primari endpoint chang baselin week exercis capac measur
distanc walk minut standard condit
year age
year age
year age
random pbo-control double-blind multi-cent trial evalu efficaci
safeti oral sgc stimul vericiguat improv physic function activ
daili live patient hfpef
primari endpoint chang kccq physic limit score baselin week
johnson
random double-blind placebo-control phase studi evalu safeti
efficaci praliciguat patient type diabet albuminuria treat renin-
primari endpoint incid treatment-emerg advers event teae studi
drug-rel teae chang baselin urin albumin creatinin ratio uacr
week
random double-blind event-driven pbo-control multicent studi effect
canagliflozin renal cardiovascular outcom subject type diabet
diabet nephropathi month
primari endpoint time first occurr event primari composit
reduct risk primari composit endpoint progress doubl
serum creatinin eskd renal cv death hr ci
reduc risk end-stag kidney diseas hr ci
reduct risk secondari endpoint mace compos
non-fatal mi non-fatal stroke cv death hr ci
reduct risk composit cv death hospit heart failur
hr ci
reduct risk hospit heart failur alon hr ci
random double-blind event-driven pbo-control multicent studi effect
dapagliflozin give addit soc prevent progress ckd cv/renal death
primari endpoint time first occurr compon composit
sustain declin egfr reach esrd cv death renal death
random day approxim year
random double-blind event-driven pbo-control multicent studi effect
finerenon reduct cardiovascular morbid mortal subject type
diabet mellitu clinic diagnosi diabet kidney diseas addit
standard care
primari endpoint time first occurr composit endpoint cardiovascular
death non-fat cardiovascular event myocardi infarct stroke hospit
heart failur time total follow month
random double-blind pbo-control multicent studi effect finerenon
subject type diabet clinic diagnosi diabet nephropathi
primari endpoint chang urinari albumin-to-creatinin ratio uacr visit
mean ratio uacr day treatment vs pbo
dose well toler safeti signal note
random double-blind multicent studi assess efficaci safeti
month oral treatment fulacimstat dose mg bid comparison placebo
top standard care patient type diabet clinic diagnosi diabet
primari endpoint chang urinari albumin creatinin ratio uacr baselin
stabl regimen glycem
control medic ace
inhibitor arb
increas rate diabet
patient-year may
gate step approv
fda previous issu
march dual sglt
type diabet per
howev drug approv
eu
stage ckd
toler label daili dose
ace inhibitor arb
stage ckd
toler label daili dose
ace inhibitor arb
stage ckd
toler label daili dose
ace inhibitor arb
hyperkalemia rate
monitor drug
moa associ
type diabet clinic
diagnosi dkd soc
label daili dose ace
inhibitor arb
compani announc plan
compani mention price
